There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

For decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient ...

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

Clinical trials suggest that the drugs seem to treat a host of other conditions, too, including addiction, Parkinson’s ...

Out-of-pocket costs for branded drugs to treat multiple sclerosis (MS), Alzheimer's, and Parkinson's disease rose from 2012 ...

The brain, traditionally considered an immune-privileged organ due to the blood-brain barrier (BBB), has its own sophisticated immune defense system.

The University of Queensland’s capabilities in drug discovery and development are set to be strengthened by a new partnership ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

6) Lecanemab: Clarivate delivers a vote of confidence in Eisai and Biogen's anti-amyloid antibody lecanemab for Alzheimer's disease – just approved by the FDA as Leqembi – after the debacle of ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

When you talk about carbohydrates, most people's minds immediately go to the culinary world. But they're also the central ...

The University of Queensland's capabilities in drug discovery and development are set to be strengthened ... suffering from ...